Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer

I F Tannock¹, G R Pond²

Affiliations

¹ Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada. Electronic address: ian.tannock@uhn.ca.
² Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada.

PMID: 25085505
DOI: 10.1093/annonc/mdu371

Free article

Comment

Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer

I F Tannock et al. Ann Oncol. 2014 Oct.

Free article

. 2014 Oct;25(10):2096.

doi: 10.1093/annonc/mdu371. Epub 2014 Aug 1.

Authors

I F Tannock¹, G R Pond²

Affiliations

¹ Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada. Electronic address: ian.tannock@uhn.ca.
² Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada.

PMID: 25085505
DOI: 10.1093/annonc/mdu371

No abstract available

PubMed Disclaimer

Comment in

Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond.
Rugo HS, Aapro M. Rugo HS, et al. Ann Oncol. 2014 Oct;25(10):2096-2098. doi: 10.1093/annonc/mdu373. Epub 2014 Aug 1. Ann Oncol. 2014. PMID: 25085504 No abstract available.

Comment on

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA 3rd. Rugo HS, et al. Ann Oncol. 2014 Apr;25(4):808-815. doi: 10.1093/annonc/mdu009. Epub 2014 Mar 10. Ann Oncol. 2014. PMID: 24615500 Free PMC article. Clinical Trial.
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A. Aapro M, et al. Ann Oncol. 2014 Apr;25(4):763-773. doi: 10.1093/annonc/mdu021. Ann Oncol. 2014. PMID: 24667713 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer

Affiliations

Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical